Tucson, AZNCT06836609Now EnrollingIRB Ready

Metabolic Dysfunction-Associated Steatotic Liver Disease Clinical Trial in Tucson, AZ

Access cutting-edge metabolic dysfunction-associated steatotic liver disease treatment through this clinical trial at a research site in Tucson. Study-provided care at no cost to qualified participants.

Sponsored by Regeneron Pharmaceuticals

Quick Self-Assessment

See if you qualify for this Tucson location

Preparing your pre-screening questions…

Expert Care in Tucson

Access metabolic dysfunction-associated steatotic liver disease specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related metabolic dysfunction-associated steatotic liver disease treatment provided free

Apply for This Tucson Location

Check if you qualify for this metabolic dysfunction-associated steatotic liver disease clinical trial in Tucson, AZ

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Tucson

    Convenient for AZ residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Tucson site if eligible
  4. 4Begin participation

About This Metabolic Dysfunction-Associated Steatotic Liver Disease Study in Tucson

This study is researching an experimental drug called ALN-CIDEB, also referred to as "study drug". The study is focused on participants with metabolic dysfunction-associated steatotic liver disease (MASLD) (Part A) and metabolic dysfunction-associated steatohepatitis (MASH) (Part B). MASLD and MASH are long-lasting liver conditions caused by having too much fat in the liver. The aim of the study is to see how safe and tolerable the study drug is. The study is looking at several other research questions, including: * What side effects may happen from taking the study drug * How the study drug works to change liver fat content * How much study drug and study drug metabolites (byproducts of the body breaking down the study drug) are in the blood at different times

Sponsor: Regeneron Pharmaceuticals

Who Can Participate

Inclusion Criteria

Part A: 18 to 55 years at Screening Visit 1 with MASLD, at Screening Visit 1 Part B: 18 to 65 years at Screening Visit 1 with a diagnosis of MASH, at Screening Visit 1
Body Mass Index (BMI) ≥30 kg/m2 and ≤40 kg/m2 at Screening Visit 1
Controlled-Attenuation Parameter (CAP) ≥285 dB/m by FibroScan during screening as described in the protocol
Liver fat content ≥8.5% by MRI-PDFF during screening
If on anti-hypertensive and/or lipid lowering medications and/or glucose lowering medications, must be on generally stable dose(s) for at least 12 weeks prior to screening and no changes to the dose(s) are anticipated during the study
Part B: A diagnosis of MASH documented in the participant's medical history, or a clinical suspicion of MASH based on non-invasive biomarkers (eg, evidence of fatty liver on imaging and elevated liver enzymes) and clinical risk factors, including having a history of 2 or more elements of metabolic syndrome, as defined in the protocol
Part B: Screening percutaneous liver biopsy NAFLD Activity Score (NAS) ≥3 and fibrosis stage, as defined in the protocol Key

Exclusion Criteria

Known historical or current diagnosis of portal hypertension or cirrhosis based on clinical assessment, imaging, and/or liver biopsy
Known historical or current diagnosis of other forms of chronic liver disease, as defined in the protocol
Prior or current suspected or known drug-induced liver injury within 1 year prior to screening
History of liver transplant, current placement on a liver transplant list, or Model for End-stage Liver Disease (MELD) score \>12
Contraindication to MRI examinations, such as persons with cardiac pacemaker and implants made of metal, severe claustrophobia, size restrictions, or other contraindications for MRI
Liver stiffness measurement, laboratory parameter assessment, estimated Glomerular Filtration Rate (GFR), and evidence of uncontrolled hypertension, as defined in the protocol
Evidence of Human Immunodeficiency Virus (HIV) infection, Hepatitis B Virus (HBV) infection, or Hepatitis C Virus (HCV) infection during screening, as described in the protocol
History of Type 1 Diabetes
Bariatric surgery, including any procedures to revise, reverse, or remove any previous bariatric surgery interventions, within approximately 5 years prior to randomization or planned during the study period NOTE: Other protocol-defined inclusion/exclusion criteria apply.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Tucson?

Yes, this clinical trial (NCT06836609) has an active research site in Tucson, AZ that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Metabolic Dysfunction-Associated Steatotic Liver Disease Treatment Options in Tucson, AZ

If you're searching for metabolic dysfunction-associated steatotic liver disease treatment options in Tucson, AZ, this clinical trial (NCT06836609) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Tucson research site is actively enrolling participants for this clinical trial. You'll receive care from experienced metabolic dysfunction-associated steatotic liver disease specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all metabolic dysfunction-associated steatotic liver disease clinical trials near you to find additional studies recruiting in your area.

More Essential Tremor Trials in Tucson, AZ

See all essential tremor clinical trials recruiting in Tucson — not just this study.

Browse Essential Tremor Trials in Tucson →

Browse More Trials by Condition

Essential Tremor TrialsAnkylosing Spondylitis TrialsLiver Disease TrialsErectile Dysfunction TrialsInterstitial Cystitis TrialsMyalgic Encephalomyelitis TrialsAll Conditions →

Ready to Join in Tucson?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Tucson, AZ